PAC MED 260mg Injection

About

PAC MED 260mg Injection contains Paclitaxel, a microtubule-stabilizing agent widely utilized in oncology for its potent antineoplastic effects. It functions by binding to tubulin, promoting the assembly of microtubules, and preventing their depolymerization. This action disrupts the dynamic equilibrium of the microtubule system, which is crucial for vital cellular functions such as mitosis and interphase transport. Consequently, cancer cells are arrested in the G2/M phase of the cell cycle, leading to programmed cell death (apoptosis). The 260mg dose is typically administered as part of a standard three-weekly chemotherapy cycle for various advanced solid tumors. Premedication is usually required to mitigate the risk of hypersensitivity reactions, which can be severe.

Uses

• Advanced ovarian cancer
• Metastatic breast cancer
• Advanced non-small cell lung cancer
• AIDS-related Kaposi's sarcoma

Directions For Use

Administer intravenously over 3 hours, typically every 3 weeks, after appropriate premedication. Strictly follow the prescribed infusion rate.

Benefits

• Highly effective against various solid tumors.
• Induces cell cycle arrest and apoptosis.
• Well-established efficacy in oncology.
• Can be combined with other chemotherapies.
• Improves disease control and survival.
• Standard treatment for several advanced cancers.

Side Effects

• Myelosuppression (neutropenia, thrombocytopenia)
• Peripheral neuropathy (dose-limiting)
• Hypersensitivity reactions (severe)
• Alopecia (complete hair loss)
• Nausea, vomiting, diarrhea
• Arthralgia/myalgia
• Mucositis
• Cardiac arrhythmias (bradycardia)
• Hypotension
• Liver enzyme elevations
• Fatigue
• Injection site reactions

Safety Measures

• Alcohol - Avoid alcohol, especially if liver function is compromised, as it may exacerbate liver toxicity, a known side effect of Paclitaxel.
• Pregnancy - Contraindicated in pregnancy due to significant potential for fetal harm. Effective contraception is mandatory during treatment and for a period after.
• Breastfeeding - Not recommended during breastfeeding due to potential harm to the infant; the drug may be excreted in human milk.
• Liver - Use with extreme caution in hepatic impairment; significant dose reductions are often necessary due to hepatic metabolism.
• Kidney - Use with caution in renal impairment; monitor kidney function, though renal excretion is a minor elimination pathway.
• Lung - Rarely, interstitial pneumonitis or pulmonary fibrosis can occur; monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.